Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.

Nathan H FowlerFelipe SamaniegoWojciech JurczakNilanjan GhoshEnrico DerenziniJames A ReevesWanda Knopińska-PosłusznyChan Yoon Y Cheah Tycel Jovelle Phillips Ewa Lech-MarandaBruce D ChesonPaolo F CaimiSebastian GrosickiLori A LeslieJulio C ChavezGustavo FonsecaSunil BabuDaniel James HodsonSpencer H ShaoJohn M BurkeJeff P SharmanJennie Y LawJohn M PagelHari P MiskinPeter SportelliOwen A O'ConnorMichael S WeissPier Luigi Luigi Zinzani

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Umbralisib achieved meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event-related discontinuations.

Keyphrases

diffuse large b cell lymphoma
hodgkin lymphoma
acute lymphoblastic leukemia
acute myeloid leukemia
risk factors
multiple myeloma
protein kinase
emergency department
adverse drug